Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Fennec Pharmaceuticals Inc. has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being handled by distinct examiners, meaning each pending matter is under the review of a different individual. Despite the separate examiners, all prosecution activity is concentrated within 1 distinct art unit, which may lead to more consistent application of legal standards compared to portfolios spread across multiple units. The focus on 1 distinct art unit suggests a very specific technical niche for these pharmaceutical filings.
The busiest examiner, CRAIG, KAILA ANGELIQUE, is responsible for 1 pending office action. This accounts for a portion of the 2 total pending actions in the portfolio. The presence of distinct examiners within a single art unit suggests that while the technical subject matter is closely related, the company must still address the specific nuances of different officials during the prosecution of their patents. Managing pending office actions across multiple examiners requires attention to the individual preferences of each official despite their shared art unit.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRAIG, KAILA ANGELIQUE | 1 | 33.8% | +25.2% |
| KWON, JOHN SEUNGJAI | 1 | 45.7% | +19.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19275772 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | CRAIG, KAILA ANGELIQUE | 33d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18375162 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | KWON, JOHN SEUNGJAI | 3d overdue |
| 19275772 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | CRAIG, KAILA ANGELIQUE | 33d |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19275772 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | CRAIG, KAILA ANGELIQUE | 1615 | §103§112 | Final Rejection | 33d | Pending | Jul 21, 2025 |
| 18375162 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | KWON, JOHN SEUNGJAI | 1615 | §103 | Non-Final OA | 3d overdue | Pending | Sep 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial